Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver: Propensity score matching analysis
Metrics: PDF 1176 views | HTML 1733 views | ?
Wang Li1,*, Yutong Bai2,*, Ming Wu2, Lujun Shen1, Feng Shi1, Xuqi Sun2, Caijin Lin2, Boyang Chang1, Changchuan Pan3, Zhiwen Li2 and Peihong Wu1
1Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 51060, P. R. China
2Zhong Shan Medical School, Sun Yat-sen University, Guangzhou 510080, People’s Republic of China
3Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Second People’s Hospital of Sichuan Province, Chengdu, Sichuan 610041, P. R. China
*Wang Li and Yutong Bai were co-first authors and contributed equally to this work
Peihong Wu, email: firstname.lastname@example.org
Keywords: Nasopharyngeal carcinoma, liver metastasis, radiofrequency ablation, palliative chemotherapy, prognosis
Received: February 25, 2016 Accepted: June 09, 2016 Published: July 02, 2016
The aim of this study was to retrospectively compare the treatment efficacy of systemic chemotherapy combined with sequential CT-guided radiofrequency ablation (Chemo-RFA) to chemotherapy alone (Chemo-only) in the management of nasopharyngeal carcinoma (NPC) with liver metastasis. Between 2003 and 2011, 328 NPC patients diagnosed with liver metastasis at Sun Yat-sen University Cancer Center were enrolled. One-to-one matched pairs between Chemo-RFA group with the Chemo-only group were generated using propensity score matching. The associations of treatment modality with overall survival (OS) and progression-free survival (PFS) were determined by Cox regression. Of the patients enrolled, 37 patients (11.8 %) received combined treatment, 291 (82.2) received chemotherapy alone. The patients in Chemo-RFA group were more frequently classified as lower number (≤3) of liver metastatic lesions (P<0.001), had lower rates of bi-lobar liver metastasis (P<0.001) and extra-hepatic metastasis (P<0.001) than patients in Chemo-only group. After propensity score matching, 37 pairs of well-matched liver metastatic NPC patients were selected from different treatment groups. The adjusted hazard ratio in OS and PFS of the choice for Chemo-RFA approach to Chemo-only was 0.53 (95%CI, 0.30-0.93) and 0.60 (95%CI, 0.36-0.97), respectively. In conclusion, combined CT-guided RFA and chemotherapy approach offer the chance of improved survival for NPC patients with oligometastasis in liver, and should be considered if the ablation is technically feasible.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.